FDA 483 OBSERVATION · #500 OF 1,000 MOST-CITED
Equipment observed, standardized, calibrated
FDA cited this observation 38 times across 38 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this observation is associated with
Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 0× the rate of the average FDA-cited firm (0.0% vs 8.3%), across 38 FEI-matched firms.
This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.
How FDA worded it — real examples
Equipment used in the compatibility testing and storage and distribution of blood and blood components is not on a regularly scheduled basis as prescribed in the SOP Manual.
Equipment used in the processing of blood and blood components is not observed, standardized and calibrated on a regularly scheduled basis as prescribed in the SOP Manual.
Equipment used in the storage and distribution of blood and blood components is not standardized and calibrated on a regularly scheduled basis as prescribed in the SOP Manual.
Equipment used in the processing of blood and blood components is not standardized on a regularly scheduled basis as prescribed in the SOP Manual.
Equipment used in the collection of blood and blood components is not observed and standardized on a regularly scheduled basis as prescribed in the SOP Manual.
Equipment used in the collection and processing of blood and blood components is not standardized and calibrated on a regularly scheduled basis as prescribed in the SOP Manual.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.
Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.